Xavier Martínez‐Gómez

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Conventional Cancer Screening versus PET/CT in Dermatomyositis/Polymyositis

Albert Selva-O’Callaghan, Josep M. Grau, Cristina Gámez‐Cenzano et al. · The American Journal of Medicine · 2010 · 149 citations

Medicine, Oncology, Radiology +12

Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients

Albert Selva-O’Callaghan, Moisés Labrador‐Horrillo, Xavier Muñoz et al. · Lupus · 2005 · 132 citations

Medicine, Immunology, Pathology +17

Myositis‐specific and myositis‐associated antibodies in a series of eighty‐eight mediterranean patients with idiopathic inflammatory myopathy

Albert Selva-O’Callaghan, Moisés Labrador‐Horrillo, Roser Solans‐Laqué et al. · Arthritis Care & Research · 2006 · 122 citations

Life Sciences, Immunology, Internal Medicine +17

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14